Fennec Pharmaceuticals (TSX:FRX) Long-Term Debt : C$41.50 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Long-Term Debt?

Fennec Pharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2023 was C$41.50 Mil.

Fennec Pharmaceuticals's quarterly Long-Term Debt increased from Jun. 2023 (C$33.73 Mil) to Sep. 2023 (C$34.69 Mil) and increased from Sep. 2023 (C$34.69 Mil) to Dec. 2023 (C$41.50 Mil).

Fennec Pharmaceuticals's annual Long-Term Debt increased from Dec. 2021 (C$6.39 Mil) to Dec. 2022 (C$33.83 Mil) and increased from Dec. 2022 (C$33.83 Mil) to Dec. 2023 (C$41.50 Mil).

Fennec Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Fennec Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Long-Term Debt Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

6.39

33.83

41.50

Fennec Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															33.83	34.40	33.73	34.69	41.50

Fennec Pharmaceuticals (TSX:FRX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Fennec Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (TSX:FRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.